Table 1 Characteristics of EC patients
From: The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer
Variables | Values |
|---|---|
Age, median (range), years | 54 (43–67) |
Surgery, n (%) | |
TH/BSO alone | 22 (44%) |
TH/BSO plus lymphadenectomy | 28 (56%) |
FIGO grade, n (%) | |
Grade 1 | 27 (54%) |
Grade 2 | 14 (28%) |
Grade 3 | 9 (18%) |
Pathologic type, n (%) | |
Type I | 33(66%) |
Type II | 17(34%) |
Stage, n (%) | |
I | 29(58%) |
II | 14(28%) |
III | 7(14%) |
Lymphovascular space involvement, n (%) | 11(22%) |
Deep (≥ 50%) myometrial invasion, n (%) | 15(30%) |
Lymph node involvement, n (%) | 9(18%) |
Adjuvant therapy, n (%) | 22(44%) |
Chemotherapy alone | 10(20%) |
Chemotherapy + Brachytherapy | 12(24%) |
Median follow up time, (95% CI), months | 65(15–79) |
Recurrence, n (%) | 8(16%) |